Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Humanigen announces first patient dosed in NIH ACTIV-5/Big Effect trial evaluating lenzilumab for Covid-19
Humanigen has announced first patient dosed in NIH ACTIV-5/Big Effect trial evaluating lenzilumab for Covid-19. (Credit: dianakuehn30010 from Pixabay)